Overview
Investors searching INJ vs MANA usually want a clear market-cap and momentum snapshot. Injective prints $5.00 (+1.77%) while MANA is at $0.066700 (+0.15%), with volume edge currently on Injective.
Quick winners
Full comparison
| Metric | INJ | MANA |
|---|---|---|
| Price | $5.00 | $0.066700 |
| Market Cap | $490.41M | $130.64M |
| FDV | — | — |
| Volume 24h | $2.50M | $244,652.86 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 213.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | MANA |
|---|---|---|
| 1H | — | — |
| 24H | +1.77% | +0.15% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | MANA |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 65.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Injective shows RSI 49.29 with trend bias neutral, while MANA sits at RSI 49.02 (bearish). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | INJ | MANA |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
MANA
Pros and cons
Pros of Injective
- INJ often anchors narratives that attract sustained media and analyst coverage.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
- Market-cap scale on Injective may dampen some idiosyncratic shocks versus smaller peers.
Cons of Injective
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
Pros of MANA
- PEPS tracking for MANA still includes AI score and level context for monitoring.
- Diversifying versus Injective with MANA can change portfolio factor exposure.
- MANA can offer higher relative beta when market attention rotates toward its niche.
Cons of MANA
- Relative underperformance versus Injective can persist through entire market regimes.
- Smaller book depth versus large caps can increase slippage for MANA.
- Higher volatility on MANA cuts both ways and demands stricter risk limits.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Injective, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
PEPS synthesizes module output into a readable pair brief. Headline stats put Injective at $5.00 and MANA at $0.066700. Relative performance over 24h (Injective) is a short window. Pair it with 30d/1y rows before inferring regime change. Return to related comparisons and individual coin intelligence pages to validate whether the relative story still holds after fresh prints.
FAQ
Which is better, Injective or MANA?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or MANA?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and MANA.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.